MicroRNA 17-92 cluster mediates ETS1 and ETS2- Dependent ras-oncogenic transformation

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Kabbout, Mohamed ^a,b,c   Dakhlallah, Duaa ^b,d   Sharma, Sudarshana ^a,c   Bronisz, Agnieszka ^a,c   Srinivasan, Ruchika ^a,b,c   Piper, Melissa ^a,d   Marsh, Clay B ^a,d   Ostrowski, Michael C ^a,c  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; MICRORNA; MICRORNA 17 92; MYC PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR ETS 2; UNCLASSIFIED DRUG; PROTEIN P21;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EMBRYO; FIBROBLAST; FLOW CYTOMETRY; GENE CLUSTER; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENOTYPE; IN VITRO STUDY; IN VIVO STUDY; INFANT; MALE; MALIGNANT TRANSFORMATION; MONOLAYER CULTURE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE C MYC; ONCOGENE ETS1; ONCOGENE ETS2; ONCOGENE H RAS; ONCOGENE RAS; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; S PHASE CELL CYCLE CHECKPOINT; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CELL LINE; DEFICIENCY; GENE INACTIVATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

ANIMALS; CARCINOGENESIS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; FIBROBLASTS; GENE KNOCKOUT TECHNIQUES; HUMANS; MALE; MICE; MICRORNAS; ONCOGENE PROTEIN P21(RAS); PROTO-ONCOGENE PROTEIN C-ETS-1; PROTO-ONCOGENE PROTEIN C-ETS-2; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84903542076     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100693     Document Type: Article

References (41)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
2. Saxena N, Lahiri SS, Hambarde S, Tripathi RP (2008) RAS: target for cancer therapy. Cancer Invest 26: 948-955.
3. Wittinghofer A (1998) Signal transduction via Ras. Biol Chem 379: 933-937.
4. Saxena N, Lahiri S, Hambarde S, Tripathi R (2008) RAS: target for cancer therapy. Cancer Invest 26: 948-955.
5. Mattingly RR (2013) Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins. ISRN Oncol 2013: 536529.
6. Klämbt C (1993) The Drosophila gene pointed encodes two ETS-like proteins which are involved in the development of the midline glial cells. Development 117: 163-176.
7. Yang BS, Hauser CA, Henkel G, Colman MS, Van Beveren C, et al. (1996) Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol Cell Biol 16: 538-547. (Pubitemid 26029092)
8. Li R, Pei H, Watson DK (2000) Regulation of Ets function by protein - protein interactions. Oncogene 19: 6514-6523. (Pubitemid 32108441)
9. Graves BJ, Petersen JM (1998) Specificity within the ets family of transcription factors. Adv Cancer Res 75: 1-55. (Pubitemid 28429032)
10. Wasylyk C, Maira SM, Sobieszczuk P, Wasylyk B (1994) Reversion of Ras transformed cells by Ets transdominant mutants. Oncogene 9: 3665-3673. (Pubitemid 24359405)
11. Langer SJ, Bortner DM, Roussel MF, Sherr CJ, Ostrowski MC (1992) Mitogenic signaling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression. Mol Cell Biol 12: 5355- 5362.
12. Hever A, Oshima RG, Hauser CA (2003) Ets2 is not required for Ras or Neu/ ErbB-2 mediated cellular transformation in vitro. Exp Cell Res 290: 132-143. (Pubitemid 37153257)
13. Galang CK, Garcia-Ramirez J, Solski PA, Westwick JK, Der CJ, et al. (1996) Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation. J Biol Chem 271: 7992-7998. (Pubitemid 26108618)
14. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT (2005) c-Mycregulated microRNAs modulate E2F1 expression. Nature 435: 839-843. (Pubitemid 40839736)
15. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261. (Pubitemid 43271657)
16. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, et al. (2006) Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38: 1060-1065. (Pubitemid 44325933)
17. Hong L, Lai M, Chen M, Xie C, Liao R, et al. (2010) The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence. Cancer Res 70: 8547-8557.
18. Wang X, Zhao X, Gao P, Wu M (2013) c-Myc modulates microRNA processing via the transcriptional regulation of Drosha. Sci Rep 3: 1942.
19. Drosten M, Dhawahir A, Sum EY, Urosevic J, Lechuga CG, et al. (2010) Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J 29: 1091-1104.
20. White MA, Nicolette C, Minden A, Polverino A, Van Aelst L, et al. (1995) Multiple Ras functions can contribute to mammalian cell transformation. Cell 80: 533-541.
21. Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, et al. (2002) Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 16: 2045-2057.
22. Treisman R (1996) Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol 8: 205-215.
23. Galang CK, Muller WJ, Foos G, Oshima RG, Hauser CA (2004) Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors. J Biol Chem 279: 11281-11292. (Pubitemid 38401625)
24. Hollenhorst PC, Jones DA, Graves BJ (2004) Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res 32: 5693-5702. (Pubitemid 39545685)
25. Eisenman RN (2001) Deconstructing myc. Genes Dev 15: 2023-2030.
26. Albert T, Wells J, Funk JO, Pullner A, Raschke EE, et al. (2001) The chromatin structure of the dual c-myc promoter P1/P2 is regulated by separate elements. J Biol Chem 276: 20482-20490.
27. Foulds CE, Nelson ML, Blaszczak AG, Graves BJ (2004) Ras/mitogen- activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Mol Cell Biol 24: 10954-10964. (Pubitemid 39603149)
28. Krumm A, Hickey LB, Groudine M (1995) Promoter-proximal pausing of RNA polymerase II defines a general rate-limiting step after transcription initiation. Genes Dev 9: 559-572.
29. Adelman K, Lis JT (2012) Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans. Nat Rev Genet 13: 720-731.
30. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, et al. (2005) A microRNA polycistron as a potential human oncogene. Nature 435: 828-833. (Pubitemid 40839734)
31. Xu D, Dwyer J, Li H, Duan W, Liu JP (2008) Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J Biol Chem 283: 23567-23580.
32. Al-azawi D, Ilroy MM, Kelly G, Redmond AM, Bane FT, et al. (2008) Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene 27: 3021-3031. (Pubitemid 351668011)
33. de Nigris F, Mega T, Berger N, Barone MV, Santoro M, et al. (2001) Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation. Cancer Res 61: 2267-2275. (Pubitemid 32692058)
34. Angstadt AY, Thayanithy V, Subramanian S, Modiano JF, Breen M (2012) A genome-wide approach to comparative oncology: high-resolution oligonucleotide aCGH of canine and human osteosarcoma pinpoints shared microaberrations. Cancer Genet 205: 572-587.
35. Williamson D, Lu YJ, Gordon T, Sciot R, Kelsey A, et al. (2005) Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol 23: 880- 888.
36. Baumhoer D, Zillmer S, Unger K, Rosemann M, Atkinson MJ, et al. (2012) MicroRNA profiling with correlation to gene expression revealed the oncogenic miR-17-92 cluster to be up-regulated in osteosarcoma. Cancer Genet 205: 212- 219.
37. Reichek JL, Duan F, Smith LM, Gustafson DM, O'Connor RS, et al. (2011) Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Clin Cancer Res 17: 1463-1473.
38. Muthusamy N, Barton K, Leiden JM (1995) Defective activation and survival of T cells lacking the Ets-1 transcription factor. Nature 377: 639-642.
39. Wei G, Srinivasan R, Cantemir-Stone CZ, Sharma SM, Santhanam R, et al. (2009) Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis. Blood 114: 1123-1130.
40. Todaro GJ, Green H (1963) Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol 17: 299- 313.
41. Wei G, Guo J, Doseff AI, Kusewitt DF, Man AK, et al. (2004) Activated Ets2 is required for persistent inflammatory responses in the motheaten viable model. J Immunol 173: 1374-1379. (Pubitemid 38924318)